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Abstract: Revolutionary advances in nanotechnology propose novel materials with superior 
properties for biomedical application. One of the most promising nanomaterials for biomedical 
application is polyhedral oligomeric silsesquioxane (POSS), an amazing nanocage consisting of 
an inner inorganic framework of silicon and oxygen atoms and an outer shell of organic groups. 
The unique properties of this nanoparticle has led to the development of a wide range of nano-
structured copolymers with significantly enhanced properties including improved mechanical, 
chemical, and physical characteristics. Since POSS nanomaterials are highly biocompatible, 
biomedical application of POSS nanostructures has been intensely explored. One of the most 
promising areas of application of POSS nanomaterials is the development of cardiovascular 
implants. The incorporation of POSS into biocompatible polymers has resulted in advanced 
nanocomposite materials with improved hemocompatibility, antithrombogenicity, enhanced 
mechanical and surface properties, calcification resistance, and reduced inflammatory response, 
which make these materials the material of choice for cardiovascular implants. These highly 
versatile POSS derivatives have opened new horizons to the field of cardiovascular implant. 
Currently, application of POSS containing polymers in the development of new generation 
cardiovascular implants including heart valve prostheses, bypass grafts, and coronary stents is 
under intensive investigation, with encouraging outcomes.
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Introduction
The emergence of advanced novel biomaterials with improved properties, capable of 
being used in several biomedical applications has revolutionized the field of   biomedical 
research in recent years. Nanomaterials are among intensively studied materials for a 
wide range of applications including biomedicine. Nanostructured composite materials 
are combinations of at least two constituent materials, a matrix (host) and a reinforce-
ment component (guest, nanofiller).1 It is known that the properties of the materials 
change considerably when the size is significantly small, ie, within 1–100 nm size range. 
Since these materials have improved physical, chemical, and mechanical properties, 
they are significantly versatile for a wide range of applications.
Nanocomposite materials are sometimes considered to be either organic, inorganic, 
or hybrid in composition.2 Bone, abalone shells, and teeth are examples of nanocom-
posites in nature. Inspired by the enhanced properties of natural nanocomposites, there 
has been much interest in preparing synthetic nanocomposites and examining their 
properties for various potential applications.3,4 The method by which nanomaterials 
are synthesized is a crucial factor behind the behavior of nanocomposite materials. International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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For instance, in the case of polymer nanocomposite, the 
synthesis method along with the nature of nanofiller, the 
method of nanoreinforcement, and the type of interaction 
between polymeric and reinforcing components regulate the 
behavior of the polymer.5 In nanocomposites, nanofillers are 
able to intercalate between the layers of matrix (intercalated 
type) or be further dispersed uniformly throughout the matrix 
to form exfoliated nanocomposites, thus maximizing the 
surface area for component interaction. While intercalated 
nanocomposites have regular interlayers, exfoliated ones 
have larger interlayers (Figure 1).
Currently available synthetic nanocomposites can be clas-
sified into clay-, carbon-, metal- and glass-reinforced.6   Silicon 
and metal oxides (eg, ZnO and TiO2) are commonly used as 
nanofillers due to their substantial mechanical properties.7 
These advanced materials have the potential to overcome the 
main restrictions and shortcomings of the standard   synthetic 
materials owing to their enhanced properties. Among the 
most commonly studied nanoparticles for developing nano-
composite materials is the silsesquioxane family.
Polyhedral oligomeric silsesquioxane 
(POSS)
The chemical structure of the silsesquioxane family is defined 
as RnSinO1.5n, which makes a structure consisting of an inner 
inorganic framework of silicon and oxygen atoms, externally 
covered by organic groups (R). R may either be hydrogen 
or an alkyl, alkene, aryl, and arylene group. Based on their 
molecular architecture, silsesquioxanes can be classified into 
two main categories of noncaged and caged nanostructure. 
The noncaged type silsesquioxane molecules can be further 
classified into random, ladder, and partial-cage   nanostructure8 
(Figure 2). Ladder like polysilsesquioxanes include 
poly(phenyl silsesquioxane),9 poly(methyl silsesquioxane),10 
and poly(hydridosilsesquioxane).11
Conventionally, cage-like silsesquioxanes appear as 
polyhedral oligosilsesquioxanes or polyhedral oligomeric 
silsesquioxanes (POSS).9 POSS is one of the molecules in the 
silsesquioxane family which has a regular three-dimensional 
(3D) shape (polyhedral = many-side, 3D) formed by a few 
units (oligomeric), each containing silsesquioxane. This is 
a structure consisting of an inner inorganic framework of 
molecular silica comprised of silicon atoms (n: 8) linked with 
oxygen atoms (n: 12) and an outer shell of organic groups 
(n: 8) that merged together to form a molecule. Hence, each 
silicon atom is bonded to three oxygen atoms and one organic 
group that may be inert or reactive. These are highly sym-
metric molecules with a nanoscopic size feature of approxi-
mately 1.5 nm in diameter including the (R) groups and can 
be considered as the smallest achievable silica particles.12
Based on the type of R group (eg, hydrogen, alkyl, 
alkylene, or aryl arylene), there are potentially an unlimited 
number of POSS types such as alkyls, olefins, alcohols, 
esters, anhydrides, acids, amines, imides, epoxies, thiols, 
sulfonates, fluoroalkyls, silanols, and siloxides. Researchers 
have shown that POSS cubes can be incorporated as building 
blocks13 to form hybrid inorganic–organic copolymers with 
improved thermal, mechanical, and physical properties.14,15 
Physical and thermal properties improved by incorporation of 
POSS include, low dielectric constants (K),16 increased glass-
transition temperature,16–18 low coefficient of thermal expan-
sion, thermal stability, and heat evolution.12,19 Improvement 
in the mechanical properties comprise tensile strength,17,18,20 
viscosity,12,20,21 and enhanced viscoelastic properties.15,22,23 
Further improvements have also been reported such as 
improved oxidation resistance, reduction of inflammability, 
oxygen permeability, and reduced inflammatory reactions, 
revealing the advantage of using these materials in various 
applications.17,18,20,24 Incorporation of POSS can change 
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Figure 2 Different structures of silsesquioxanes: ladder structure (A), partial cage 
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the surface properties including hydrophobicity, surface 
energy, and surface topography. Efficient surface coverage 
and stability to a variety of conditions are part of POSS 
derivative’s features that make them attractive to be used as 
surface modification agents or other useful modifiers.25 Using 
POSS as a noncovalent modifier, a variety of 3D aggregates 
has been recently obtained from various nanoparticles such 
as palladium, magnetic, and gold nanoparticles.26–31 The 
unique characteristics of POSS nanoparticles offers diverse 
application potential in a wide range of areas, including the 
biomedical field, which is intensely under investigation.
Biomedical applications of POSS
The unique structure and superior properties of POSS allow 
them to be used in the structure of different polymers and 
copolymers developed for various biomedical applications. In 
particular, owing to their biocompatibility and ability to incor-
porate with different polymers, POSS nanostructures have been 
shown to offer high potential for several biomedical applications 
such as drug delivery,32,33 dental composites,34 biosensors,35 
biomedical devices,36–38 and tissue engineering.39,40 Due to their 
inert nature and low inflammatory response, the framework of 
POSS, consisting of Si-O and Si-C, is very similar to silicone, 
which has been a preferable biomaterial since the 1960s, when 
it was introduced in breast implantation.41 Biocompatibility is 
the main characteristic of POSS, resulting from the increased 
surface energy in the foci of silicon-rich areas. Nontoxicity and 
cytocompatibility are other features of POSS, making them suit-
able for biomedical application.42–44 Hence, polymeric POSS-
based nanocomposites have been largely studied by material 
scientists with the aim of using them in the biomedical field, 
in particular cardiovascular devices.
Distinctive features of POSS 
nanocomposites for cardiovascular 
application
Application of biomaterials in cardiovascular system and blood 
contacting devices necessitates specific characteristics such 
as blood compatibility and antithrombogenicity. To meet the 
essential requirements for these applications, we have devel-
oped a nanocomposite material by introducing POSS moieties 
into poly(carbonate-urea)urethane (POSS-PCU) as a pendent 
chain. Studies on its cytocompatibility, antithrombogenicity, 
and biostability have shown that this new nanocomposite 
polymer has unique characteristics for these applications.45 
This nanocomposite can be   bio-functionalized by modification 
of the surface to attract endothelial progenitor cells from the 
circulatory blood and become endothelialized to enhance bio- 
and blood-  compatibility of the cardiovascular devices made 
with this material (Figure 3). POSS-PCU has been character-
ized and assessed for biomedical applications in general and 
for cardiovascular application in particular, and the results of 
these studies reveal that POSS-PCU nanocomposite contains 
enhanced characteristics for these applications.
Mechanical properties
The development of cardiovascular devices such as pros-
thetic heart valves from polymeric materials requires a broad 
understanding of the basic mechanical and surface proper-
ties of the polymer. In a study,37 the mechanical properties 
of POSS–PCU, including tensile strength, tear strength, and 
hardness, were tested and compared with control (PCU). 
The surface properties were analyzed using contact angle 
measurement, and the resistance to platelet adhesion was 
also investigated. POSS–PCU (hardness 84 ± 0.8 Shore A) 
demonstrated significantly higher tensile strength 53.6 ± 3.4 
and 55.9 ± 3.9 N mm−2 at 25°C and 37°C, respectively) than 
PCU (33.8 ± 2.1 and 28.8 ± 3.4 N mm−2). Tensile strength 
and elongation at break of POSS–PCU was significantly 
higher than PCU at both 25°C and 37°C. POSS–PCU 
showed a relatively low Young’s modulus (25.9 ± 1.9 and 
26.2 ± 2.0 N mm−2), which was significantly greater in com-
parison with control PCU (9.1 ± 0.9 and 8.4 ± 0.5 N mm−2) 
at 25°C and 37°C, respectively. There was no significant 
difference in tear strength between POSS–PCU and PCU at 
25°C.   However, tear strength increased significantly (at 37°C) 
Figure  3  Biofunctionalization  of  the  surface  to  enhance  in  situ  endothelialization. 
Biofunctionalized surface of the heart valve leaflets made from POSS-PCU nanocomposite 
can  target  several  biological  processes  to  promote  in-situ  endothelialization,  by 
promoting the mobilization of EPC from the bone marrow, encouraging cell-specific 
(circulating EC, EPC, and stem cells) homing to the vascular graft site, providing cell-
specific adhesion motifs on the vascular grafts (of a predetermined spatial concentration), 
and directing the behavior of the cells post-adhesion to rapidly form a mature fully 
functioning endothelium with self-repair capability. 
Copyright© 2008. American Chemical Society. Adapted with permission from De Mel 
A, Jell G, Stevens MM, Seifalian AM. Biofunctionalization of biomaterials for accelerated 
in situ endothelialization: a review. Biomacromolecules. 2008;9(11):2969–2979.65
Abbreviations: EC, endothelial cell; EPC, endothelial progenitor cells; POSS-PCU, 
polyhedral oligomeric silsesquioxane-poly(carbonate-urea)urethane.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
778
Ghanbari et al
as the thickness increased from 100 µm (51.0 ± 3.3 N mm−1) 
to 200 µm (63 ± 1.5 N mm−1). The surface of POSS–PCU 
was significantly less hydrophilic than that of PCU. Thus, the 
mechanical characterization of the nanocomposite has proven 
to be an ideal candidate for the use in cardiovascular devices, 
in particular, synthetic heart valve leaflet application.
We have also developed and assessed a small porous 
caliber bypass graft made of POSS-PCU nanocomposite 
via an extrusion-phase-inversion manufacturing technique. 
Mechanical and elemental analysis (using energy-dispersive 
x-ray analysis) showed a uniform distribution of POSS on 
the outer and inner surface of the graft with a favorable 
mechanical integrity for hemodynamic contacts.38
Degradative resistance
Initial expectations were that the presence of POSS nanocores in 
POSS-PCU material would hold together all the components of 
the polyurethane and thus prevent degradation thereby further 
improving upon the degradative resistance of polyurethanes. 
Polymer degradation of these nanocomposites was classified 
into three categories, namely physiological, oxidative, and 
hydrolytic. Fourier transform infrared (FTIR) analyses of 
the nanocomposite exposed to differing plasma protein frac-
tions (PF I-IV) showed no difference in intensities of ‘Si–O’, 
‘C–O–C’, ‘NH–CO’ (urea), and ‘(NHCO)O’ (urethane) bonds 
for each bond wavelength as compared with the control.46 These 
results indicate that biological proteins have a negligible deg-
radative effect on these POSS-PCU nanocomposites.
Thermal analysis of the most severely degraded POSS-
PCU nanocomposites showed that glass transition tempera-
ture (Tg), an indicator of the soft phase of a polymer, did not 
vary significantly between the nondegraded and degraded 
samples, thus seconding the data on stress–strain analysis 
of the nanocomposite grafts. It was found that the addition 
of POSS-nanocores to PCU increased the final melting 
temperature of the nanocomposite by approximately 30°C 
while decreasing the Tg by a further 10–12°C.46 This paradox 
may be explained by the fact that nanocores prevent close 
packaging of polymer chains due to thermal rearranging, 
which in turn result in an increase in dynamic voids within the 
  polymer. This extra space allows for earlier segmental mobil-
ity of the polymer chain and therefore lowering the Tg.
The increase in melting temperature (Tm), and the lesser 
phase separation on the other hand, are attributable to the 
increased nanoscale interactions between its constituents, 
thus binding together the POSS-PCU nanocomposites. 
  Furthermore, nanofilled-polyurethane (PU), unlike PCU, 
which shows three-phase melting, exhibited a single-phase 
melting process with higher temperatures at which softening 
occurs. In the t-butyl-degraded samples, the melt process was 
two-phased with lower softening temperatures.46 These results 
again signal that both hard and soft phases of the polymer inte-
grate to a far greater extent than in PCU due to the nanoscale 
interaction of the POSS-nanocages with the soft phase.
Biocompatibility and biostability
To assess biocompatibility, sheets of POSS-PCU were 
implanted subcutaneously into the back of normal, healthy 
adult sheep for 36 months. After 36 months, the implants 
were removed from the animals under general anesthesia, 
and the surrounding tissue and capsule, if any, was taken 
for histopathological examination. The explanted nanocom-
posites exhibited no evidence of an inflammatory layer or 
capsule formation.47
Attenuated total reflectance (ATR)-FTIR analysis 
of the implanted 2% POSS-PCU sheets showed that the 
‘Si–O’ bonds at 1109 cm−1 wavelengths within the closed 
nanocage were intact in all the six samples of the nanocom-
posite and on both surface and bottom in different regions of 
the   polymer. Scanning electron microscopy (SEM) analyses 
on the explanted nanocomposite samples showed no signifi-
cant difference in its surface morphology as compared with 
the undegraded control POSS-PCU nanocomposite.47
The findings showed that POSS-PCU nanocomposites 
are ideal for use at the biological interface as tissue implants, 
biomedical devices, and even vascular grafts due to the very 
low levels of inflammation elicited by the host to it. This can 
be due to the intrinsic surface roughness of the polymer caus-
ing increased contact angle hysteresis and conformational 
change in adsorbed surface fibrinogen; a key initiator for 
foreign-body reactions.
endothelialization property
Formation of an endothelial cell layer on the surface of 
cardiovascular implants enhances the bio- and hemocompat-
ibility of these devices. In particular, the improvement of the 
endothelialization of the luminal surface of bypass grafts, 
potentially improve their patency rate and overall clinical 
outcomes.48 Studies have shown the clinical benefit of lining 
polytetrafluoroethylene (PTFE) vascular grafts with endothe-
lial cells, particularly in lower limb arterial bypass grafts,49 
unlike native, uncoated polyethylene terephthalate grafts. 
In an in-vitro study using human umbilical vein endothelial 
cells (HUVECs), we assessed whether this nanocomposite International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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is safe and compatible with in vitro cell cultures. Apart from 
indicating its safety as a biomaterial at the cellular level, such 
information would also serve as a measure of its potential 
for developing bio-hybrid vascular grafts.
Compared with existing silicone copolymers,49–51 we 
found that the use of a POSS-based nanocomposite improves 
cell adhesion characteristics. As these nanocages occupy 
minimal volumes within the polymer, relatively greater 
surface areas of PU are available which allows for improved 
endothelialization. This would also confer a greater degree 
of polarity to the polymer which could explain its superior 
hydrophobicity to PCU.
These experiments also indicate that once adherent 
to its surface, endothelial cells (ECs) are also capable of 
proliferating manifold to form a confluent monolayer. 
While the PicoGreen® assay showed excellent proliferating   
characteristics of ECs on the polymer, light microscopic 
analysis revealed how this occurred. Prior to achieving cel-
lular confluence, the ECs aligned in a reticular manner. The 
intervening areas were subsequently filled in to achieve cel-
lular   confluence.45 It has also been shown that exposing the 
EC-seeded POSS-PCU conduits to the low shear stress before 
being exposed to physiological shear stress significantly 
enhanced cell adherence rate. The findings approved potential 
benefits of the pre-seeding method followed by low shear 
stress and confirmed the potential of POSS-PCU for potential 
application in tissue-engineered cardiovascular devices.52
To enhance endothelialization potential, POSS-PCU can 
be biofunctionalized by modification of its surface using 
biofunctional peptides such as RGD (arginine-glycine-
aspartic acid), a functional part of an extracellular matrix 
component, fibronectin. In an in-vitro study, RGD-modified 
POSS-PCU sheets were assessed to evaluate cell adhesion 
and proliferation using peripheral blood mononuclear cells 
(PBMCs) containing endothelial progenitor cells (EPCs). The 
experimental data showed that the quality of cell adhesion 
and proliferation on the polymer was excellent.48 Qualitative 
data using SEM analysis clearly visualized the presence 
of optimal cell–polymer interactions with the formation 
of numerous filopodia at its surface, flattened ECs, and no 
rounded cells. This suggests that these ECs are capable of 
morphogenesis and have the ability to proliferate well. In 
another study, the RGD-modified POSS-PCU was used to 
develop a porous small diameter bypass graft and tested under 
static and pulsatile conditions. In this study PBMC containing 
EPCs isolated from adult healthy volunteers were cultured on 
nanocomposite graft and evaluated for the cell attachment, 
growth, and endothelialization using Alamar Blue assay, 
SEM, and immunostaining for endothelial cell markers, 
including CD34, CD31, and eNOS. This study showed that 
POSS-PCU has the bio-functionalization capability, and 
is able to provide cell growth and cell viability and have a 
great potential for rapid endothelialization from peripheral 
blood cells.53 Selective biofunctionalization using specific 
growth factors together with other surface modification tech-
niques such as creating specific surface nanotopography can 
potentially enhance the affinity of the surface to ECs while 
minimizing possible attachment and proliferation of other 
cells such as smooth muscle cells or fibroblasts.
Natural regenerative capacity of the body can be utilized 
to induce endothelialization of cardiovascular devices. In 
a very recent study, we assessed the potential of in-situ 
endothelialization of a heart valve made from POSS-PCU 
nanocomposite. Peripheral blood mononuclear cells were 
separated using Ficoll-Paque centrifugation, with har-
vested EPCs purified using CD34 microbead labeling and 
magnetic-activated cell sorting (MACS). Cells were seeded 
onto 96-well plates coated with POSS-PCU or GRGDG/
GRGDG-LA modified POSS-PCU and PCU polymer controls 
for a period of 21 days. The cultured cells were studied under 
light, confocal, and SEM. In addition, fluorescence-activated 
cell sorting (FACS) was used to analyze cell surface mark-
ers including CD34, CD133, VEGFR2, CD144, CD31, and 
vWF in order to identify EPCs’ potential proliferation and 
differentiation toward mature endothelial cells. Cell attach-
ment and growth were observed in all POSS-PCU samples, 
with significantly higher activity than seen within the control 
polymers (P , 0.05). Microscopic examination revealed 
clonal expansion and morphological changes in cells seeded 
on POSS-PCU, GRGDG, and GRGDG-LA modified poly-
mers. The frequency of triple-positive EPC (cells positive 
for CD34, CD133, and VEGFR2) was increased over time of 
culture, revealing the proliferation capacity of cultured EPCs. 
After one week of culture, SEM showed a mixed population 
of morphologically differentiated endothelial cells and EPCs. 
The cells expressed increasing levels of mature endothelial 
cell markers (CD31, vWF, CD144, and VEGFR2) over time 
with a confluent layer of EC on day 21 (Figure 4). These results 
support the self-endothelialization potential of cardiovascular 
implants made with the POSS-PCU polymer and the concept 
of the possibility of an in-vivo tissue engineering approach 
by the use of the natural regenerative capacity of EPCs and 
smart synthetic surfaces based on POSS-modified nanocom-
posite materials.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Anti-thrombogenic potential
To assess the antithrombogenic property of POSS, we 
used thromboelastography (TEG), a sensitive indicator of 
  thrombogenicity. This was used as a screening test to ascer-
tain the anti-thrombogenic properties of POSS-PCU. It was 
found that the polymer had significantly lower maximum 
amplitude values indicative of decreased platelet bonding 
strength as compared with control polystyrene and PCU. 
In addition, it was also found that the clots which formed 
on POSS-PCU were significantly unstable and lysed by 
60 minutes compared with PCU or the control polystyrene 
polymer.54
Direct enzyme-linked-immunosorbent serologic assay 
(ELISA) fibrinogen adsorption analyses to the various poly-
mers showed that there was a significantly decreased fibrino-
gen adsorption to the polyurethanes (POSS-PCU and PCU) 
as compared with PTFE. In the case of POSS-PCU, this may 
again be attributed to the effect of POSS groups on the PCU 
surface, which possess an unstable surface free energy and 
hence reduce both platelet and protein adsorption. Although 
we found no significant difference between POSS-PCU and 
PCU in terms of fibrinogen adsorption,   Thromboelastography 
(TEG) analyses showed that the strength of the fibrin clot 
in POSS-PCU is much weaker as compared with PCU. 
This indicated that while the amount of fibrinogen adsorbing 
to both polymers are similar, the binding strength is weaker 
in POSS-PCU compared with PCU alone.
Platelet adsorption onto casted sheets of POSS-PCU was 
significantly less than both PCU and PTFE sheets in vitro 
after 120 minutes in contact. There was significant difference 
in platelet adsorption by 120 minutes between POSS-PCU, 
PCU, and PTFE. In conjunction with the lower maximum 
amplitude values obtained on TEG, this suggests that POSS-
PCU has an anti-platelet effect by both repelling their surface 
adsorption and lowering the binding strength of platelets to 
the polymer which correspond to the poor adsorption charac-
teristics exhibited towards fibrinogen as discussed above.47,54 
The rate of platelet activation was also significantly lower 
in POSS-PCU samples. Direct ELISA analysis of the con-
centration of platelet factor 4 (PF4) released from platelets 
on the polymer surface was quantified. Significantly less 
concentration of PF4 was found from the supernatants of 
platelets incubated on POSS-PCU surface compared with 
the PCU control.
Resistance to calcification and fatigue
Calcification is a limiting factor in biomedical application of 
synthetic materials. In particular, it is considered as the main 
restricting factor of successful application of polymeric heart 
valves.55 Calcification also represents a major cause of failure 
of biological tissue heart valves. It is a complex phenomenon 
influenced by a number of biochemical and mechanical 
  factors. In a study,36 the calcification-resistance efficacy and 
fatigue behavior of POSS-PCU were assessed by means of 
in-vitro testing. In particular, thin sheets of nanocomposite, 
glutaraldehyde fixed bovine pericardium (BP) and PU were 
exposed to a calcium solution into a specially designed in-
vitro accelerated physiological pulsatile pressure system, for 
a period of 31 days and a total of 40 × 106 cycles. The samples 
were investigated for signs of calcification after exposure to 
calcium solution by means of x-ray, microscopic, and chemical 
inspections. Mechanical and surface properties were also stud-
ied using stress strain behavior and surface morphology and 
hydrophobicity. Comparison showed that, in the experimental 
conditions, the level of calcification for the nanocomposite 
was considerably lower than for the fixed BP and PU samples 
(Figure 5). Also, mechanical properties were unchanged in 
POSS-PCU, while there was a significant deterioration in 
PU samples. Hydrophobicity significantly reduced in both 
POSS-PCU and PU samples. However, the POSS-PCU nano-
composite remained more hydrophobic than the PU sample. 
Less platelet adhered to the POSS-PCU compared with PU.36 
A
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Figure  4  Morphological  changes  of  isolated  cells  cultured  on  POSS-PCU 
nanocomposite polymer. Spindle-shaped morphology of early EPCs at day 7 (A) 
has been dominated by cobble stone-shaped features at day 21 (B) characteristics 
for the late ePCs or eCs; immunostaining of the cultured cells at day 14. Cells were 
stained for vwF (C) and veGFR2 (D), showing positive expression of these cell 
surface markers on the cultured cells. 
Abbreviations: EC, endothelial cell; EPC, endothelial progenitor cells; POSS-PCU, 
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These results indicate that the use of this nanocomposite in 
synthetic leaflets heart valves may lead to potential advantages 
in terms of long-term performance and durability.
Reduced inflammatory response
Inflammatory response, which is mainly triggered by foreign-
body reaction after transplantation, is also a determinant 
factor of biocompatibility and long-term durability of the 
biomedical implants. Inflammatory response is a very 
complex immunologic reaction involving various types of 
immune cells and immunomediators such as cytokines. All 
forms of implantation involve some degree of tissue injury, 
which will initiate two principal reactions, namely inflamma-
tion and the related response of repair. It is still incompletely 
understood; ie, which type and extent of inflammation favors 
optimal biocompatibility, and how precisely physicochemi-
cal properties of the biomaterials induce specific biological 
responses. However, it is well known that increased immune 
response and inflammatory reactions diversely affects the 
implant-host interaction, leading to unfavorable outcomes. 
In this in-vitro setting, we investigated potential inflam-
matory reactions induced by POSS-PCU compared with 
other polymers. Peripheral blood mononuclear cells were 
exposed to the polymeric disks for one week, and the acti-
vation of inflammatory cells was assessed by evaluation 
of cell surface markers and cytokine release. The study 
revealed that the level of pro-inflammatory cytokines, 
namely interleukin-1 (IL-1β/IL-1F2) and tumor necrosis 
factor (TNFα/TNFSF1A) were significantly lower in the 
supernatant collected from POSS-PCU samples compared 
with the control PCU. This was in association with reduced 
expression of CD86 and CD69, which are leukocyte activa-
tion markers. The study revealed that incorporation of POSS 
into the PCU polymer can effectively reduce any possible 
inflammatory reaction resulting from the implantation of 
the biomedical devices made with these materials. It also 
enhances the hemocompatibility of cardiovascular devices 
by eliminating the well known effect of leukocyte activation 
on thrombosis formation.
Development of cardiovascular 
implants using POSS
The enhanced characteristics of POSS-PCU make it an 
ideal material of choice for the development of advanced 
cardiovascular implants. This polymer is currently being 
used in the fabrication of many biomedical devices, including 
synthetic leaflet heart valves, percutaneous valve prostheses, 
small and large diameter bypass graft, and coated stents, and 
stent grafts.
Development of novel synthetic  
leaflet heart valve
Heart valve replacements are among the most widely used 
cardiovascular devices and are in rising demand. Currently, 
clinically available devices are restricted to the mechanical 
and bioprosthetic valves which are associated with significant 
complications and drawbacks, mainly unsolved hemocompat-
ibility problems of mechanical prostheses and poor durability 
of bioprosthetic counterparts. Synthetic leaflet heart valves 
based on newly emerged superior materials represent an attrac-
tive alternative to the existing prostheses, merging superior 
durability of mechanical valves and enhanced hemodynamic 
function of bioprosthetic valves. A novel synthetic leaflet heart 
valve has been in our lab using POSS-PCU nanocomposite 
as leaflet material37 (Figure 6). As POSS-PCU has been 
demonstrated to be safe, resistant to degradation, mechani-
cally strong, able to be neo-endothelialized, biocompatible, 
and anti-thrombogenic, it can play a major role in the next 
generation of artificial heart valves. A novel polymeric heart 
valve design has been invented at University College London 
(UCL) which is based on a design strategy aimed at reduc-
ing the energy absorbed during the operating cycle, which 
results in high hydrodynamic performances and reduced stress 
  levels. The enhanced hemodynamic performance of the UCL 
valve suggests that the proposed design is a good choice for 
developing a synthetic leaflet heart valve. This together with 
BP PU POSS-PCU
0
2
4
6
8
10
C
a
l
c
i
u
m
 
c
o
n
c
e
n
t
a
r
a
t
i
o
n
 
(
 
×
 
1
0
0
 
µ
g
/
c
m
2
)
Figure 5 Chemical analysis of calcium deposition. Quantitative analysis of calcium 
deposition  on  the  samples  showed  significantly  reduced  calcium  deposition  on 
POSS-PCU  compared  with  BP  (P  , 0.001,  n  = 5)  and  in  comparison  with  PU 
(P , 0.05, n = 5). 
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AB
Figure 6 A) Trileaflet heart valve design (UCL design) with complex geometry 
and additional reflection on the leaflets to improve hemodynamic performance and 
durability. B) A valve prototype fabricated from POSS-PCU nanocomposite with a 
Dacron suture ring. 
Abbreviations: POSS-PCU, polyhedral oligomeric silsesquioxane-poly(carbonate-
urea)urethane; UCL, University College London.
advanced POSS-PCU nanocomposite material with improved 
properties as the leaflet material indicates that UCL synthetic 
leaflet heart valve can be considered as a real breakthrough in 
the development of synthetic leaflet heart valve with potential 
successful clinical application, overcoming the limitations of 
the current prostheses.
Percutaneous low profile valve 
prostheses
Conventional open heart surgery for heart valve replacement 
consists of partial or complete sternotomy with extracorporeal 
circulation and cardioplegic cardiac arrest. This approach, in 
the case of the aortic valve replacement, is associated with 
high mortality rate (ranging from 10% to 50%) in high-risk 
patients with severe co-morbidities such as left ventricular 
failure, concomitant coronary artery disease with prior 
bypass surgery, chronic obstructive pulmonary disease, and 
advanced age.56 Enormous development in interventional 
cardiology offers trans-catheter percutaneous techniques 
which could significantly reduce morbidity and mortality of 
valve repair or replacement, especially in high-risk elderly 
patients. Developing percutaneous valve replacement could 
extend treatment to those who are not currently considered 
for surgery and to those who are in early stages of valvular 
heart disease, and the treatment would avoid the onset of 
progressive ventricular dysfunction.57 Early results of experi-
mental and clinical trials of percutaneous valve replacement 
are promising; however, the technique is in the early stage 
of its development with irrefutable potential problems 
which should be resolved. For instance, currently, modi-
fied bioprosthetic tissue valves are being used in minimally 
invasive valve replacement with concomitant complications. 
Advanced polymeric materials with improved properties can 
potentially be used as leaflet materials in percutaneous heart 
valves. The use of synthetic materials enables the   reduction 
of the leaflet thickness and therefore the overall profile of 
the valve. It also grants more consistent manufacturing tech-
niques and eliminates the problem of tissue dehydration in 
the crimped state, which is one of the main complications 
of tissue valves. Using POSS-PCU nanocomposite, a novel 
aortic valve sui for trans-catheter aortic valve implantation 
is being developed by our group at UCL, aimed at over-
coming the main limitations experienced with currently 
available percutaneous devices. The valve consists of three 
polymeric leaflets (POSS-PCU nanocomposite) attached to a 
self-expandable nitinol wire stent. The stent design provides 
a high expanded/collapsed diameter ratio and enhanced 
anchoring through sufficient radial and axial forces. The 
device is fully retrievable and repositionable, which is one 
of the main advantages of this device.
Coronary artery bypass grafts and 
abdominal aortic aneurysms (AAA) grafts
Coronary artery bypass surgery is one the most common 
cardiac surgeries worldwide. Currently, autologous blood 
vessels, such as the saphenous vein, are the conduits of choice 
for revascularisation. However, up to 30% of patients who 
require surgery do not have suitable or sufficient blood ves-
sels to be used for transplantation due to vascular disease, 
amputation, or previous harvest. Furthermore, harvesting 
autologous vessels requires a second surgical procedure, with 
potential concomitant morbidies. Despite the critical need 
for synthetic small caliber grafts, success has been limited 
to the replacement of large caliber vessels, such as the aorta, 
where polyethylene terephthalate (PET) and expanded poly-
tetrafluoroethylene (ePTFE) are the current industry standard 
biomaterials demonstrating impressive 3-year patency rates 
of over 90%.58 The replacement of small caliber vessels with 
synthetic grafts has been largely disappointing, with 2-year 
patency rates of 40% for the femoropopliteal position.59,60 
Failure has been attributed primarily to thrombus formation, 
due to the inherent thrombogenicity of the synthetic surface, 
and intimal hyperplasia as a result of a mechanical mismatch 
between the elastic artery and rigid graft.61–63 A novel small 
diameter vascular graft with an internal diameter of 5 mm has 
been developed using POSS-PCU nanocomposite by utiliza-
tion of thermally induced phase separation (TIPS) method 
which was shown to be compliant in nature, minimizing the 
mechanical mismatch between graft and artery (Figure 7). 
This graft has been studied in vitro and in vivo for hemo-
compatibility and reveals excellent patency rates in animal 
models and currently undergoing clinical trials.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Along these lines, a large diameter abdominal aortic 
aneurism bypass graft is also being developed by the use of 
POSS-PCU and casting method. The graft is reinforced by 
self-expandable nitinol stent to be delivered via the vascular 
system using percutaneous approaches. Early results of the 
in-vitro tests of this innovative device are promising.
Development of nanocomposite-coated 
coronary stents and stent grafts
Application of POSS-PCU nanocomposite for coating 
coronary stents has also been explored by our group. Using 
electrohydrodynamic spraying or ultrasound atomization 
approaches, we have established the application of POSS-
PCU for the coating of metallic stents and demonstrated that 
this novel polymeric nanocomposite has the potential to be 
used for development of new generation stents with improved 
properties, especially in small-diameter stents including 
coronary artery stents.64 The coating would improve the 
hemocompatibility and patency rate of the commercially 
available stents which are prone to thrombosis and obstruc-
tion in long-term clinical use.
Discussion
Application of currently available cardiovascular implants is 
associated with serious complications and drawbacks, mainly 
due to poor hemocompatibility, inadequate durability, and 
lack of sufficient autologous replacements. Development of 
new generation implants based on advanced novel materi-
als can potentially overcome the main problems in current 
clinical practice. The candidate material for this particular 
application should offer enhanced hemocompatibility and 
biostability to ensure improved long-term performance of 
the implant. POSS-PCU, as a paradigm POSS material, is 
a pioneering prototype of advanced novel materials which 
possesses superior hemocompatibility, biostability, anti-
thrombogenicity, and calcification resistance, owing to its 
enhanced physicochemical properties and nanoreinforced 
structure and surface nanotopography. Its superior proper-
ties compared with conventional polymers are among the 
main advantages of using this material in the cardiovascular 
system. Early results of the development of small diameter 
bypass grafts and heart valve prototypes using this novel 
nanocomposite have been very promising. However, long-
term in-vitro and in-vivo assessments are required in order 
to identify possible limitations and tangible advantages or 
disadvantages of using these new generation implants in real 
clinical practice. POSS nanocages have been incorporated 
into other polymeric systems, which have been explored for 
a wide range of biomedical applications, even though there 
is no report of cardiovascular applications of other POSS 
nanocomposites, to the best of our knowledge.
In-situ endothelialization of the implant surfaces is an 
interesting concept which can tremendously improve the 
hemocompatibility of these devices. This can be achieved 
by the use of state of the art surface modification techniques 
and the natural capacity of the human body. EPCs in the 
circulatory blood system hold great promises for this concept. 
Therefore, creating a smart surface to attract EPCs from 
peripheral blood, avoid excessive proliferation of smooth 
muscle cells and fibroblast, and retain a viable layer of 
A
B
Figure 7 A) Scanning electron microscope pictures of endothelial cell adhesion   
morphology on POSS-PCU showing the presence of flat, spindle-shaped cells with 
numerous filopodia and the absence of cell retraction. This indicates the viability and 
proliferation of these cells on POSS-PCU at 48 hours (320× magnification). B) An 
explanted POSS-PCU bypass graft demonstrated to be endothelialized and patent 
after a 2 year implantation in a sheep model.
Abbreviation: POSS-PCU, polyhedral oligomeric silsesquioxane-poly(carbonate-
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functional endothelium is a challenging area which requires 
more research attention.
Conclusion and future prospects
The distinctive characteristics of POSS nanocomposites 
offer potential advantages over conventional polymers, in 
particular for cardiovascular applications. A novel POSS 
nanocomposite has been proposed for development of 
cardiovascular implants. The combination of POSS mol-
ecules with PCU polymer has resulted in a POSS-PCU 
nanocomposite with improved properties such as enhanced 
hemocompatibility, biostability, calcification resistance, 
and superior biomechanical features, which can be used in 
cardiovascular implants. With a nanocomposite suitable for 
cardiovascular application, attempts are now focused on 
development of new generation cardiovascular devices with 
improved hemocompatibility and long-term performance. 
As POSS nanomaterials are safe, resistant to degradation, 
compliant, allow neo-endothelialization, biocompatible and 
anti-thrombogenic, the probability of vascular occlusion is 
low. If successful in the long run, the clinical implications 
would be tremendous, as the superior properties of the new 
generation cardiovascular implants could overcome the 
complications and limitations of currently available devices. 
Projects on the development of percutaneous heart valves, 
coated stents and bypass grafts based on these POSS con-
taining novel nanocomposites are currently active. Primary 
results of heart valve prototypes and coronary artery bypass 
grafts, fabricated from this novel nanocomposite, are very 
promising. Besides the mentioned properties, resistance to 
calcification, enhanced mechanical and surface properties, 
capability of grafting bioactive peptides to enhance attach-
ment, proliferation, and differentiation of circulatory stem 
cells into endothelial cells are among other advantages of 
using these materials in the development of cardiovascular 
devices. By the emergence of new generation cardiovas-
cular devices based on POSS nanomaterials, it is likely to 
overcome some of the major problems of current implants, 
saving lives and improving the quality of life of a significant 
number of patients.
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